As the House prepared to vote on
a new version of the 21st Century Cures Act, IDSA wrote in support
and highlighted the provisions addressing antibiotic R&D, the future
research workforce, and the opioid epidemic as essential.
In May, the House of Representatives launched its 21st
Century Cures Initiative aimed at engaging stakeholders to develop policies
that will help bring new drugs to market. In response to a request for input,
IDSA highlighted the need for new incentives and regulatory changes to spur
R&D for new antibiotics and rapid diagnostics as well as public health
interventions to slow the rise of resistance.
One dozen pharmaceutical companies signed a letter to Congress in support of the LPAD approval pathway (as proposed by IDSA) for antibacterials to treat serious or life-threatening infections with few, if any, satisfactory therapeutic options.
1300 Wilson Boulevard Suite 300 Arlington, VA 22209 | Phone: (703) 299-0200 | Fax: (703) 299-0204
| HIVMA | Contact Us
© Copyright IDSA 2016 Infectious Diseases Society of America